$1.23 Million in Sales Expected for AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) This Quarter

Equities analysts expect AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) to announce sales of $1.23 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for AcelRx Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $1.16 million and the highest estimate coming in at $1.30 million. AcelRx Pharmaceuticals posted sales of $610,000.00 during the same quarter last year, which would indicate a positive year-over-year growth rate of 101.6%. The business is expected to announce its next earnings report on Thursday, March 5th.

According to Zacks, analysts expect that AcelRx Pharmaceuticals will report full-year sales of $3.04 million for the current fiscal year, with estimates ranging from $2.97 million to $3.10 million. For the next fiscal year, analysts anticipate that the business will report sales of $35.39 million, with estimates ranging from $32.17 million to $38.60 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that follow AcelRx Pharmaceuticals.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings data on Wednesday, November 6th. The specialty pharmaceutical company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.07. The firm had revenue of $0.61 million for the quarter, compared to analysts’ expectations of $1.22 million.

A number of brokerages have recently weighed in on ACRX. Zacks Investment Research upgraded AcelRx Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $2.25 target price on the stock in a report on Monday, November 11th. Credit Suisse Group downgraded AcelRx Pharmaceuticals from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $7.00 to $2.00 in a report on Monday, November 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of AcelRx Pharmaceuticals in a report on Friday, November 8th. Four investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. AcelRx Pharmaceuticals currently has an average rating of “Buy” and an average target price of $6.46.

In related news, Director Mark G. Edwards purchased 25,000 shares of the stock in a transaction on Tuesday, November 12th. The shares were bought at an average price of $1.78 per share, for a total transaction of $44,500.00. Following the completion of the acquisition, the director now directly owns 243,750 shares in the company, valued at approximately $433,875. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 7.50% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. WINTON GROUP Ltd bought a new stake in shares of AcelRx Pharmaceuticals in the second quarter valued at approximately $40,000. Wells Fargo & Company MN boosted its position in shares of AcelRx Pharmaceuticals by 15.4% in the second quarter. Wells Fargo & Company MN now owns 254,709 shares of the specialty pharmaceutical company’s stock valued at $644,000 after acquiring an additional 33,910 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of AcelRx Pharmaceuticals by 573.3% in the second quarter. Charles Schwab Investment Management Inc. now owns 191,483 shares of the specialty pharmaceutical company’s stock valued at $485,000 after acquiring an additional 163,045 shares during the period. Bank of New York Mellon Corp boosted its position in shares of AcelRx Pharmaceuticals by 306.1% in the second quarter. Bank of New York Mellon Corp now owns 253,974 shares of the specialty pharmaceutical company’s stock valued at $643,000 after acquiring an additional 191,432 shares during the period. Finally, Northern Trust Corp boosted its position in shares of AcelRx Pharmaceuticals by 122.4% in the second quarter. Northern Trust Corp now owns 290,252 shares of the specialty pharmaceutical company’s stock valued at $734,000 after acquiring an additional 159,744 shares during the period. Institutional investors own 23.19% of the company’s stock.

Shares of ACRX remained flat at $$1.86 during trading hours on Wednesday. The stock had a trading volume of 757,019 shares, compared to its average volume of 1,476,130. The company has a market cap of $144.42 million, a price-to-earnings ratio of -2.30 and a beta of 2.02. AcelRx Pharmaceuticals has a one year low of $1.64 and a one year high of $4.09. The firm has a fifty day moving average of $1.96 and a 200 day moving average of $2.32.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Featured Story: Euro STOXX 50 Index

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.